Galactosylhydroxylysine and pyridinium cross links in monitoring the bone response to hormone replacement therapy.
Aim of the study was to compare urinary galactosyl-hydroxylysine (GHyl), deoxypyridinoline (D-Pyr) and pyridinoline (Pyr) before and after 5 to 9 months of hormone replacement therapy (HRT) in postmenopausal women. The urinary markers were measured by HPLC in the second void of fasting samples and were expressed as ratio to creatinine. GHyl was also expressed as a ratio to glucosylgalactolysyl-hydroxylysine (GGHyl). After short-term hormone replacement therapy, urinary D-Pyr fell significantly, but Pyr and GHyl, also when expressed as a ratio to GGHyl, remained unmodified. We conclude that GHyl and Pyr are not useful markers in monitoring the bone response to HRT in postmenopausal women.
Marabini
R
R
Unità Metabolica dell'Osso, Istituto Scientifico H. San Raffaele, Italy.
Sirtori
P
P
Chionna
R
R
Barzizza
L
L
Rubinacci
A
A
D000469:Alkaline Phosphatase / Q000097:blood; D015415:Biomarkers; D015519:Bone Density; D001842:Bone and Bones / Q000378:metabolism*; D002118:Calcium / Q000652:urine; D002851:Chromatography, High Pressure Liquid; D003432:Cross-Linking Reagents; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D006901:Hydroxylysine / Q000031:analogs & derivatives* / Q000652:urine; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D017698:Postmenopause; D011726:Pyridinium Compounds / Q000652:urine*
D015415:Biomarkers; D003432:Cross-Linking Reagents; D011726:Pyridinium Compounds; D015675:Osteocalcin; D006901:Hydroxylysine; C007817:galactosylhydroxylysine; D000469:Alkaline Phosphatase; D002118:Calcium